China Post-marketing Surveillance (PMS) Study of Fabrazyme®

    Not Recruiting
  • End date
    May 11, 2023
  • participants needed
  • sponsor
    Genzyme, a Sanofi Company
Updated on 13 May 2022
replacement therapy
neuropathic pain
agalsidase beta
cornea verticillata


This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with Fabry Disease.


Study participation for each patient will be total of 54 weeks which will include 4 weeks of screening, 48 weeks of treatment period and 2 weeks of post study treatment observation

Condition Fabry's Disease
Treatment agalsidase beta
Clinical Study IdentifierNCT05054387
SponsorGenzyme, a Sanofi Company
Last Modified on13 May 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note